Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19 SPONSOR: Mountain Valley MD $MVMD.ca $CTLT $MRNA $NVAX

Posted by AGORACOM at 12:53 PM on Friday, January 15th, 2021

SPONSOR: Mountain Valley MD has confirmed the ability to make the drug ivermectin water-soluble without the use of organic solvents, greatly increasing the potential applications for treatment. MVMD has Improved ivermectin’s water solubility by nearly 5000 times more than current solubility  Click Here for More Info

  • The NIH has upgraded their recommendation and now consider IVERMECTIN an option for use! The national Institute of Health

Recommendation

  • The COVID-19 Treatment Guidelines Panel (the Panel) has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

Rationale

Ivermectin is an antiparasitic drug that is approved by the Food and Drug Administration (FDA) for the treatment of onchocerciasis and strongyloidiasis. Ivermectin is not FDA-approved for the treatment of any viral infection. In general, the drug is well tolerated. It is currently being evaluated as a potential treatment for COVID-19.

Antiviral and Anti-Inflammatory Effects of Ivermectin

Reports from in vitro studies suggest that ivermectin acts by inhibiting the host importin alfa/beta-1 nuclear transport proteins, which are part of a key intracellular transport process that viruses hijack to enhance infection by suppressing the host antiviral response.1,2 In addition, ivermectin docking in vitro may interfere with the attachment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human cell membrane.3

Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell culture. However, pharmacokinetic and pharmacodynamic studies suggest that ivermectin doses up to 100-fold higher than those approved for use in humans would be required to achieve the plasma concentrations necessary to duplicate the drug’s antiviral efficacy in vitro.4,5 Even though ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) against SARS-CoV-2 in vitro.6,7

Ivermectin demonstrates potential anti-inflammatory properties in some in vitro studies,8,9 properties which have been postulated to be beneficial in the treatment of COVID-19.10

Clinical Data

Since the last revision of the Ivermectin section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as preliminary, non-peer-reviewed reports. Some clinical studies showed no benefits or worsening of disease after ivermectin use,11-14 whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19,15-18 greater reduction in inflammatory markers,16,17 shorter time to viral clearance,11,16 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.11,16,18

However, most of the studies reported to date had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. The missing information and limitations include the following:

  • The sample size of most of the trials was small.
  • Various doses and schedules of ivermectin were used.
  • Some of the randomized controlled trials were open-label studies in which neither the participants nor the investigators were blinded to the treatment arms.
  • In addition to ivermectin or the comparator drug, patients also received various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin.
  • The severity of COVID-19 in the study participants was not always well described.
  • The study outcome measures were not always clearly defined.

Because of these limitations, the Panel cannot draw definitive conclusions about the clinical efficacy or safety of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

SOURCE: https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/

Gratomic $GRAT.ca $CBULF Defines Product Marketing Strategy as Construction Advances at Aukam Graphite Mine $NGC.ca $LLG.ca $GPH.ca $NOU.ca $NMI.ca #TODAQ

Posted by AGORACOM at 8:15 AM on Friday, January 15th, 2021
  • Foundations of its product marketing and sales strategy have been officially defined

Gratomic Inc. (TSXV:GRAT)(FSE:CB82)(WKN:A143MR)(OTCQB:CBULF) is pleased to announce that the foundations of its product marketing and sales strategy have been officially defined.

During the commissioning phase, due to begin in March 2021, the company will be testing production quality and quantity. In order to support this development, Gratomic has plans in place to upgrade its laboratory facilities at Aukam. This will enable us to properly characterize the initial production batches generated during the commissioning process, and feedback the information to our Process Control, in order to define parameters required to ensure repeatability and efficiency of the production.

As a supplement to our main strategic focus on the battery industry and graphene applications (see press release from Dec 30th, 2020), Gratomic will pursue the development of graphite grades commonly used in applications such as graphitic foil, lubricants, crucibles, refractories, friction materials and ceramics, among others.

This will allow the Company to diversify our portfolio and optimize the output of the processing plant. Filling the remainder of the Aukam Book in terms of offtake and purchase schedules. In the coming weeks, Gratomic will pursue the preparation of samples for 53 graphite end users around the world, in order to begin the testing and homologation procedures that precede the use of our product into the most technical applications.

Gratomic’s Product Marketing team has requested an additional 550 kg of graphite samples be shipped to Toronto for conversion to SG16 Battery Grade product specifications in addition to the initial shipment of 243Kg of graphite, which was previously dispatched (see press release from Oct 28,2020). Both samples are destined for distribution to Battery OEM Manufacturers.

Read More: https://agoracom.com/ir/Gratomic/forums/discussion/topics/753096-gratomic-defines-product-marketing-strategy-as-construction-advances-at-aukam-graphite-mine/messages/2298104#message

VIDEO – After Record Q3 and YTD Results, Datametrex $DM.ca $DTMXF Starts 2021 With 23,000 #COVID Test Sales To Film Industry For ~ $4M $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:34 PM on Thursday, January 14th, 2021

Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker. 

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter

If that wasn’t enough, they started off 2021 by announcing the following:

  • Sold over 23,000 onsite tests for the film industry at locations in Montreal, Toronto and Vancouver for the months of October through December 2020. This represents approximately $4,000,000 CAD in top-line revenue for Q4
  • Datametrex Providing COVID-19 Testing for Air Canada Front-Line and Inflight Employees
  • Binding LOI to acquire 100% of Concierge Medical Consultant Inc. a private telehealth and medical concierge services company currently generating revenue through a direct-to-consumer subscription model

Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

AGORACOM Small Cap 60: Durango Resources $DGO.ca Drilling The Trove Property in Windfall Lake Adjoining Osisko $OSK.ca $BTR.ca $SII.ca $TLG.ca

Posted by AGORACOM at 2:45 PM on Thursday, January 14th, 2021

Highlights:

  • Maiden Drill program underway at Trove
  • Located in Windfall Lake gold District
    • Surrounded by Osisko
  • 100% interest in the Trove and East Barry claims
  • Currently the most active gold exploration camp in Canada
    • 21 drill rigs at Windfall in 2020
  • 40% Inside Ownership
    • Marcy Kiesman, President & CEO owns 16%
  • Positioned for Discovery in Windfall Lake

Four Cannabis Resolutions for 2021 SPONSOR: Harborside $HBOR.ca $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 2:27 PM on Thursday, January 14th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564690/hub/Harborside_Inc2_logo.png

SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California

  • Here are four resolutions for conscientious local cannabis consumers to consider.

By all accounts, the Bay Area cannabis industry did remarkably well for itself in 2020.

Forced to deal with new COVID-19 restrictions, a crumbling economy, fallout from multiple wildfires, and a string of high-profile robberies, cannabis companies still managed to rake in close to $1 billion for California in state tax revenue alone.

At the same time, the window for equity brands to establish a viable foothold in the industry continues to rapidly close.

It’s now been a full three years since California’s adult-use market began in earnest. That’s a lot of time for consumers to develop brand loyalty, be it on the product side or the shops they frequent. Nonetheless, the time required to move through San Francisco’s equity program means that a number of new, equity-owned businesses are just now getting off the ground.

And they could use your help. In fact, there’s a number of ways individuals can make a difference! On that note — and in the spirit of starting 2021 on the right foot — here are four resolutions for conscientious local cannabis consumers to consider.

Shop Equity-Owned

There are two types of dispensaries that exist in San Francisco: those that were grandfathered in from the Prop. 215 days and those owned by equity operators. To be sure, there are plenty of great pot shops that fall into the former category, but in the spirit of spreading the love around, it’s also extremely important to support the new crop of Black and brown-owned dispensaries now open in the city if we hope to see them endure. In 2020 alone, new shops to open from equity owners include Stiiizy-Union Square (SF’s first dispensary owned by a Latina woman) and Posh Green (SFs first dispensary owned by a Black woman). There is also a newly created “SF Equity” seal that customers can look for when shopping for local products across all categories. More new shops, including one affiliated with the combo print shop and arcade, Free Gold Watch, are expected to open in 2021 as well.

Tour a Legal Grow

It may sound like a flowery platitude, but to truly understand cannabis, one should really see it grow. In the past, such a visit might have put you at risk of doing time, but nowadays, there are legal opportunities for individuals or groups to tour outdoor and indoor grow sites. Walking between rows of towering plants at the peak of harvest is something everyone should experience. From the scents to the scale to the solace, there is so much to soak in at a cannabis farm. As an added bonus, you’ll likely also get to meet the farmers responsible for growing your medicine. They can tell you about the ways smoke changes sunlight, which in turn affects terpene output. They can share their personal stories of what led them to this career (hint: when it comes to craft growers, the answer is not “getting rich”)

Cook with Cannabis

If we haven’t yet arrived at the molecular gastronomy phase of the cannabis cooking revolution, it’s assuredly coming soon. From the golden days of brownies baked by intuition, the modern edibles market is, by contrast, a brain-bursting cornucopia of choice and potential confusion. If you’re tired of trying to understand the difference between live resin and raw flower or continue to question how dosing works, why not get a little hands-on experience? The time has quite honestly never been better to bring cannabis into your home kitchen. Local cannabis chef (and Mellows founder) Stephanie Hua has a cookbook to guide newbies along, while San Francisco’s Potli prides itself on offering products designed to serve as staples of a cannabis-friendly pantry. Once you’ve tackled a few recipes on your own, you’ll likely have a far more nuanced appreciation for all of the many ingredients that go into preparing an infused edible!

Support Pot Non-Profits

Yes, 2020 was a big year for people asking for money. No, that’s not likely to end anytime soon. Of the many worthy causes in need of your funds, several groups focused on advocacy and racial justice within the legalized cannabis space are notably also seeking donations. In the Bay Area, Oakland’s the Hood Incubator is calling for financial contributions. It’s difficult to overstate how the industry — both in the Bay Area as well as across California — might look without their tireless efforts to empower local equity applicants to reach the finish line and remain viable. Another one to consider is the California chapter of the National Organization for the Reform of Marijuana Laws (NORML). Advocates for patients and sensible drug laws, it’s likely both CA NORML as well as the organization’s national wing will both be very busy this year as the prospect of federal decriminalization (or outright legalization) continues to gain traction in Congress.

SOURCE: https://www.sfweekly.com/culture/pacific-highs/four-cannabis-resolutions-for-2021/

Gratomic $GRAT.ca Announces Update on Construction at Aukam Graphite Project $NGC.ca $LLG.ca $GPH.ca $NOU.ca $NMI.ca #TODAQ

Posted by AGORACOM at 1:43 PM on Thursday, January 14th, 2021

Gratomic Inc. (“Gratomic” or the “Company”) (TSXV:GRAT)(FRANKFURT:CB82) (WKN:A143MR) (OTCQB: CBULF) is pleased to announce that it has completed the settling reservoir on the mine site and has begun the commissioning process on the settling and water filtration tanks. The Company is thrilled to report that it remains on target for its planned commissioning in March of 2021.

Gratomic has mobilized a crane through local company, Coleman Transport, located in Rosh Pinah, Namibia. Coleman Transport will assist the team with the placement of the custom engineered plant equipment to allow for final assembly. The custom equipment arrived on site in October as per the Press Release dated October 15th, 2020 (http://gratomic.ca/2020/10/15/gratomic-one-step-closer-to-completion-of-aukam-processing-plant/).

The Aukam team will begin commissioning the crushing and grinding circuit the third week of January. Steel Frames and Structures are expected to be installed by the 25th of January.

READ MORE: https://agoracom.com/ir/Gratomic/forums/discussion/topics/753029-gratomic-announces-update-on-construction-at-aukam-graphite-project/messages/2297926#message

AGORACOM Small Cap 60: Valeo Pharma $VPH.ca $VPHIF Discusses Health Canada Approval for Redesca™ and Redesca Hp™ $30 Million Forecasted Annual Peak Sales $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:14 PM on Thursday, January 14th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Commercial launch to impact first half 2021 revenue
  • $30 million forecasted annual peak sales
  • 8 years of proven in-market safety Internationally
  • Low molecular weight heparin increasingly used to prevent COVID-19 driven complications

“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly  being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.

Hub On AGORACOM / Corporate Profile

American Creek Resources $AMK.ca: New Treaty Creek Report $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca $AOT.ca $ESK.ca

Posted by AGORACOM at 9:04 AM on Thursday, January 14th, 2021
American Creek Provides Update on Its First Quarter Filings

Treaty Creek resource could represent one of the largest gold deposit discoveries found in North America in the past 10 years!”

“If Tudor Gold lives up to the high expectations of market participants and has a powerful gold resource of 15-30 million ounces of gold on Treaty Creek, we believe that an unprecedented takeover battle for one of the most attractive gold projects in Canada will ensue”

These statements are taken from JS Research’s latest report (found below) on Treaty Creek and our JV partner Tudor Gold.  The report highlights this year’s 45,600m program at Treaty Creek as we look forward to the initial resource calculation on the property. 

The Treaty Creek Project is a Joint Venture with Tudor Gold owning 3/5th and acting as operator. American Creek and Teuton Resources each have a 1/5th interest in the project creating a 3:1 ownership relationship between Tudor Gold and American Creek. American Creek and Teuton are both fully carried until such time as a Production Notice is issued, at which time they are required to contribute their respective 20% share of development costs. Until such time, Tudor is required to fund all exploration and development costs while both American Creek and Teuton have “free rides”.
 
American Creek has not independently confirmed the technical information in the JS Research report. 

READ MORE: https://agoracom.com/ir/AmericanCreek/forums/discussion/topics/753006-american-creek-resources-new-treaty-creek-report/messages/2297840#message

3 Days After #Draganfly $DFLY.ca $DFLYF CEO Cam Chell Says “I’ll Build The Company Into One of The Top Three Drone Companies”, Company Announces #NASDAQ Intentions $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 8:04 AM on Thursday, January 14th, 2021

Most of us know drones as cool toys flying around the neighbourhood, or perhaps even as simple commercial applications for things like real estate videos. 

But the fact of the matter is that drone usage is about to go parabolic with huge corporations now testing ways to:

  • Use drones to provide Internet connections in remote locations. 
  • Use drones to collect crowd data.
  • ….. And there’s even a start-up that’s using drones to deliver tacos to your door.

In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones (hardware) to data … and one company is already ahead of the shift … DraganFly (DFLY: CSE) (DFLYF:OTCQB) (3U8:FSE)

DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:

  • Established in 1998 DFLY is considered the oldest commercial drone company in the world
  • Built the first drone that saved a life
    • Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
  • Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
  • Detect infectious conditions in a person from a distance of 190 feet
  • Conduct phenotyping, data collection and analysis by the USDA

Clients include:

  •  Ford
  • Warner Brothers
  • Suncor Energy
  • Shell
  • Redbull
  • Government of Canada 
    • Ontario Provincial Police, 
    • Australian Federal Police, 
    • Royal Canadian Mounted Police, 
    • Illinois State Police, 
    • Shell
    • Dow 

Most recently, DFLY’s Vital Intelligence technology was selected for implementation by Knightscope, a leader in a leader in autonomous robot security capabilities.  

With all of this under the Company’s belt, it’s easy to see why CEO Chell believes DFLY will become one of the top 3 drone companies in the world and why they have now begun the process of listing on NASDAQ.

If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or are just learning, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.